{"success":true,"data":{"pressRelease":{"id":"30639","rtpr_id":"nACShwdVpa","ticker":"ORIC","exchange":"NASDAQ","all_tickers":["ORIC"],"title":"INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc. - ORIC","author":"ACCESSWIRE","published_at":"2026-05-11T22:15:00.704Z","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May\n11, 2026 / Pomerantz LLP is investigating claims on behalf of investors of\nORIC Pharmaceuticals, Inc. (\"Oric\" or the \"Company\") (NASDAQ:ORIC). Such\ninvestors are advised to contact Danielle Peyton at newaction@pomlaw.com or\n646-581-9980, ext. 7980.\n\nThe investigation concerns whether Oric and certain of its officers and/or\ndirectors have engaged in securities fraud or other unlawful business\npractices.\n\n[Click here for information about joining the class action]\n(https://pr.report/lgnz)\n\nOn March 31, 2026, Oric issued a press release \"announced a rinzimetostat\n(ORIC-944) program update\" indicating that its prostate cancer treatment is\nroughly as effective as a competitor in the same class - falling short of\nexpectations that the drug would be the best in its class of PRC2 blockers.\n\nOn this news, Oric's stock price fell $5.20 per share, or 41%, to close at\n$7.48 per share on April 1, 2026.\n\nPomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris,\nand Tel Aviv, is acknowledged as one of the premier firms in the areas of\ncorporate, securities, and antitrust class litigation. Founded by the late\nAbraham L. Pomerantz, known as the dean of the class action bar, Pomerantz\npioneered the field of securities class actions. Today, more than 85 years\nlater, Pomerantz continues in the tradition he established, fighting for the\nrights of the victims of securities fraud, breaches of fiduciary duty, and\ncorporate misconduct. The Firm has recovered numerous multimillion-dollar\ndamages awards on behalf of class members. See www.pomlaw.com.\n\nAttorney advertising. Prior results do not guarantee similar outcomes.\n\nSOURCE: Pomerantz LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-1165970)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACShwdVpa","title":"INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc. - ORIC","author":"ACCESSWIRE","ticker":"ORIC","created":"2026-05-11T22:15:00.704Z","tickers":["ORIC"],"exchange":"NASDAQ","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May\n11, 2026 / Pomerantz LLP is investigating claims on behalf of investors of\nORIC Pharmaceuticals, Inc. (\"Oric\" or the \"Company\") (NASDAQ:ORIC). Such\ninvestors are advised to contact Danielle Peyton at newaction@pomlaw.com or\n646-581-9980, ext. 7980.\n\nThe investigation concerns whether Oric and certain of its officers and/or\ndirectors have engaged in securities fraud or other unlawful business\npractices.\n\n[Click here for information about joining the class action]\n(https://pr.report/lgnz)\n\nOn March 31, 2026, Oric issued a press release \"announced a rinzimetostat\n(ORIC-944) program update\" indicating that its prostate cancer treatment is\nroughly as effective as a competitor in the same class - falling short of\nexpectations that the drug would be the best in its class of PRC2 blockers.\n\nOn this news, Oric's stock price fell $5.20 per share, or 41%, to close at\n$7.48 per share on April 1, 2026.\n\nPomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris,\nand Tel Aviv, is acknowledged as one of the premier firms in the areas of\ncorporate, securities, and antitrust class litigation. Founded by the late\nAbraham L. Pomerantz, known as the dean of the class action bar, Pomerantz\npioneered the field of securities class actions. Today, more than 85 years\nlater, Pomerantz continues in the tradition he established, fighting for the\nrights of the victims of securities fraud, breaches of fiduciary duty, and\ncorporate misconduct. The Firm has recovered numerous multimillion-dollar\ndamages awards on behalf of class members. See www.pomlaw.com.\n\nAttorney advertising. Prior results do not guarantee similar outcomes.\n\nSOURCE: Pomerantz LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-1165970)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-05-11T22:15:00.721921418Z","server_sent_at_ms":1778537700721},"received_at":"2026-05-11T22:15:00.776Z","source_url":"https://www.accessnewswire.com/newsroom/en/business-and-professional-services/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-1165970"},"analysis":{"id":"22699","press_release_id":"30639","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC).\n\nThe investigation focuses on whether Oric and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.\n\nOn March 31, 2026, Oric announced that its prostate cancer treatment, rinzimetostat (ORIC-944), is roughly as effective as a competitor, falling short of expectations for the best-in-class PRC2 blocker.\n\nAs a result, Oric's stock price fell $5.20 per share, or 41%, to close at $7.48 per share on April 1, 2026.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[{"name":"Danielle Peyton","role":"contact at Pomerantz LLP"}],"products":["rinzimetostat (ORIC-944)"],"companies":[{"name":"Pomerantz LLP","relationship":"plaintiff law firm"},{"name":"ORIC Pharmaceuticals, Inc.","ticker":"ORIC","relationship":"target"}],"dollarAmounts":[{"amount":"$5.20","context":"stock price decline per share"},{"amount":"$7.48","context":"closing stock price on April 1, 2026"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Pomerantz Law Firm. No new disclosure from the issuer; no certified class, no settlement. Boilerplate lead-plaintiff-deadline reminder."},"tickerRelevance":{"others":[],"primary":"ORIC"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC).\n\nThe investigation focuses on whether Oric and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.\n\nOn March 31, 2026, Oric announced that its prostate cancer treatment, rinzimetostat (ORIC-944), is roughly as effective as a competitor, falling short of expectations for the best-in-class PRC2 blocker.\n\nAs a result, Oric's stock price fell $5.20 per share, or 41%, to close at $7.48 per share on April 1, 2026.","key_figures":{},"named_entities":{"people":[{"name":"Danielle Peyton","role":"contact at Pomerantz LLP"}],"products":["rinzimetostat (ORIC-944)"],"companies":[{"name":"Pomerantz LLP","relationship":"plaintiff law firm"},{"name":"ORIC Pharmaceuticals, Inc.","ticker":"ORIC","relationship":"target"}],"dollarAmounts":[{"amount":"$5.20","context":"stock price decline per share"},{"amount":"$7.48","context":"closing stock price on April 1, 2026"}]},"model_name":"Qwen/Qwen2.5-72B-Instruct-AWQ","prompt_hash":"sha256:a76fb3b19e8e8b7b","schema_hash":"sha256:8658c370b800cf3d","created_at":"2026-05-12T02:11:31.468Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":91293,"modelName":"george-droid-qwen-72b"}}